Sairopα’s anti-CTLA4 Antibody Shows Clinical Efficacy with a Mild Safety Profile


June 1, 2024 – ROTTERDAM, Netherlands – Sairopα, a leading developer of innovative cancer therapies, unveiled encouraging results from its dose-escalation Phase 1 study of ADU-1604 (anti-CTLA4 antibody) in advanced PD-1 relapsed/refractory melanoma patients at the ASCO Annual Meeting 2024 in Chicago. The study demonstrated that ADU-1604 is well tolerated across multiple dosages with no dose-limiting toxicities. Early signs of clinical efficacy were noted, particularly with a dose-dependent increase in CD8+ T-cell proliferation correlating with tumor reduction. The ongoing dose-expansion phase will further evaluate the 225mg dosage in 20 additional patients to support future combination therapies.